The price is subject to availability. Please contact us to confirm. 

Lorbrena/Lorviqua (lorlatinib) is a medicine indicated for the treatment of previously treated patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).

The medicine is marketed in the USA under the brand name Lorbrena, and in the EU under the brand name Lorviqua. We use the name Lorbrena throughout this page.

What is Lorbrena (lorlatinib)?

Lorbrena (lorlatinib) is a medicine indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on:

• crizotinib and at least one other ALK inhibitor for metastatic disease; or
• alectinib as the first ALK inhibitor therapy for metastatic disease; or
• ceritinib as the first ALK inhibitor therapy for metastatic disease.

It is available in tablet form each containing 25 mg or 100 mg of lorlatinib^[1].

*KINDLY CONTACT US NOW ………

*Call, Text Or Whats-App :…………((((( +1 424–488–3777 )))))

*E-Mail Address:……..((((( [email protected] )))))

*Website:……(((( http://rchemicalsonline.com )))))

How does Lorbrena (lorlatinib) work?

Lorbrena (lorlatinib) is a kinase inhibitor acting by interfering with ALK protein activity. Buy Lorbrena 100mg Tablets

Read more…

In patients with ALK-positive non-small cell lung cancer, a mutation in the ALK gene causes the production of defective ALK protein. This results in the uncontrolled production of cancerous cells. The active ingredient in Lorbrena, lorlatinib, targets the mutant ALK protein and blocks the growth of cancer. Buy Lorbrena 100mg Tablets